Home
HelpTest Code CLFAT Cryptococcus Antigen Titer, Lateral Flow Assay, Spinal Fluid
Useful For
Monitoring Cryptococcus antigen titers in cerebrospinal fluid
Aiding in the diagnosis of cryptococcosis
This test should not be used as a test of cure or to guide treatment decisions.
Disease States
- Cryptococcosis
Reporting Name
Cryptococcus Ag Titer, LFA, CSFSpecimen Type
CSFSpecimen Required
Container/Tube: Sterile vial
Specimen Volume: 0.5 mL
Specimen Minimum Volume
0.3 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| CSF | Refrigerated (preferred) | 14 days | |
| Frozen | 14 days |
Reject Due To
| Gross hemolysis | Reject |
Clinical Information
Cryptococcosis is an invasive fungal infection caused by Cryptococcus neoformans or Cryptococcus gattii. C neoformans has been isolated from several sites in nature, particularly weathered pigeon droppings. C gattii was previously only associated with tropical and subtropical regions. More recently, however, this organism has been found to be endemic in British Columbia and the Pacific Northwestern United States and is associated with several different tree species.
Infection is usually acquired via the pulmonary route. Patients are often unaware of any exposure history. Approximately half of the patients with symptomatic disease have a predisposing immunosuppressive condition such as AIDS, steroid therapy, lymphoma, or sarcoidosis. Symptoms may include fever, headache, dizziness, ataxia, somnolence, and cough. While the majority of C neoformans infections occur in immunocompromised patient populations, C gattii is has a higher predilection for infection of healthy individuals.(1,2)
In addition to the lungs, cryptococcal infections frequently involve the central nervous system (CNS), particularly in patients infected with HIV. Mortality among patients with CNS cryptococcosis may approach 25% despite antibiotic therapy. Untreated CNS cryptococcosis is invariably fatal. Disseminated disease may affect any organ system and usually occurs in immunosuppressed individuals.
Interpretation
The presence of cryptococcal antigen in any body fluid (serum or cerebrospinal fluid [CSF]) is indicative of cryptococcosis.
Disseminated infection is usually accompanied by a positive serum test.
Declining titers may indicate regression of infection. However, monitoring titers to cryptococcal antigen should not be used as a test of cure or to guide treatment decisions. Low-level titers may persist for extended periods of time following appropriate therapy and resolution of infection.(3,4)
According to the College of American Pathologists (CAP, IMM.41840), CSF specimens submitted for initial diagnosis that test positive by the lateral flow assay, should also be submitted for routine fungal culture. Culture can aid in differentiating between the 2 common Cryptococcus species causing disease (Cryptococcus neoformans and Cryptococcus gattii) and can be used for antifungal susceptibility testing, if necessary. CSF specimens submitted to monitor antigen levels during treatment do not need to be cultured.
Cautions
A traumatic lumbar puncture and contamination of the cerebrospinal fluid (CSF) specimen with serum may lead to a positive Cryptococcus antigen result from CSF in patients without neuroinvasive cryptococcosis.
Cryptococcus antigen titers acquired by the lateral flow assay may be higher than titers achieved by other Cryptococcus antigen assays. Titers acquired by different assay methods are not interchangeable.
Cryptococcus antigen titers should be followed using the same assay.
A positive result is indicative of cryptococcosis; however, all test results should be reviewed in light of other clinical findings.
A negative result does not preclude diagnosis of cryptococcosis, particularly if only a single specimen has been tested and the patient shows symptoms consistent with cryptococcosis.
Testing should not be performed as a screening procedure for the general populations and should only be performed when clinical evidence suggests the diagnosis of cryptococcal disease.
Although rare, extremely high concentrations of cryptococcal antigen can result in weak test lines and in extreme instances, yield negative test results.
This assay has not been evaluated for cross-reactivity in patients with trichosporonosis.
Supportive Data
Endpoint titers between the IMMY lateral flow assay (LFA) and the Meridian latex agglutination test were compared for 18 cerebrospinal fluid (CSF) samples positive for Cryptococcus antigen. While the overall qualitative correlation was good, these data indicate that the endpoint titer achieved by the IMMY LFA was at least 2-fold higher than that achieved by the Meridian latex agglutination assay in 15 of 17 (88%) serum samples (Table). Therefore, Cryptococcus antigen titers should be monitored by using the same method on serially-collected samples; titers acquired by different methods are not interchangeable.
Table. Reciprocal endpoint titer
|
CSF sample |
Meridian latex agglutination |
IMMY LFA |
|
1 |
>256 |
5120 |
|
2 |
2 |
80 |
|
3 |
128 |
40 |
|
4 |
64 |
640 |
|
5 |
2 |
10 |
|
6 |
>256 |
5120 |
|
7 |
128 |
40 |
|
8 |
>256 |
640 |
|
9 |
>256 |
5120 |
|
10 |
32 |
256 |
|
11 |
256 |
10,240 |
|
12 |
64 |
640 |
|
13 |
64 |
2560 |
|
14 |
>256 |
10,240 |
|
15 |
32 |
640 |
|
16 |
>256 |
10,240 |
|
17 |
64 |
2560 |
|
18 |
1 |
5 |
Clinical Reference
1. Speed B, Dunt D: Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. Clin Infect Dis. 1995;21(1):28-34
2. Chen S, Sorrell T, Nimmo G, et al: Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study Group. Clin Infect Dis. 2000 Aug;31(2):499-505.doi: 10.1086/313992
3. Lu H, Zhou Y, Yin Y, Pan X, Weng X: Cryptococcal antigen test revisited: significance for cryptococcal meningitis therapy monitoring in a tertiary Chinese hospital. J Clin Microbiol. 2005 June;43(6):2989-2990
4. Perfect JR, Dismukes WE, Dromer F, et al: Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010 Feb 1;50(3):291-322
5. Warren NG, Hazen KC: Candida, Cryptococcus, and other yeasts of medical importance. In: Marrya PR, ed. Manual of Clinical Microbiology. 7th ed. ASM Press; 1999:1184-1199
6. Perfect JR: Cryptococcosis (Cryptococcus neoformans and Cryptococcus gattii). In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 9th ed. Elsevier; 2020:3146-3161
Method Description
The Cryptococcus antigen (CrAg) lateral flow assay is a sandwich immunochromatographic assay. Specimens and diluent are added to a test tube and the lateral flow device is added. The test uses specimen wicking to capture gold-conjugated, anti-cryptococcal antigen monoclonal antibodies and gold-conjugated control antibodies deposited on the test membrane. If cryptococcal antigen is present in the specimen, it binds to the gold-conjugated, anti-cryptococcal antigen antibodies. This complex wicks up the membrane and interacts with the test line, which has immobilized anti-cryptococcal antigen monoclonal antibodies. The antigen-antibody complex forms a sandwich at the test line causing a visible line to form. A valid test shows a visible line at the control line. Positive test results create 2 lines (control and specimen), while negative results form only the control line.(Package insert: CrAg Lateral Flow Assay. IMMY; Rev 06/27/2019)
Day(s) Performed
Monday through Sunday
Report Available
Same day/1 to 2 daysSpecimen Retention Time
14 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.CPT Code Information
87899
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| CLFAT | Cryptococcus Ag Titer, LFA, CSF | 9817-8 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 62076 | Cryptococcus Ag Titer, LFA, CSF | 9817-8 |
Method Name
Lateral Flow Assay (LFA)
Secondary ID
62076Forms
If not ordering electronically, complete, print, and send Infectious Disease Serology Test Request (T916) with the specimen.